The Generalized Anxiety Disorder Scale (GAD-2) is a clinically useful and psychometrically valid tool for screening anxiety symptoms in multiple sclerosis (MS) rehabilitation and neurology care settings, according to a recent study. Importantly, this tool has the potential to identify individuals with MS who are at risk for anxiety disorders and who may benefit from rehabilitation psychology interventions to ultimately improve functioning and quality of life. The sample was comprised of 99 adults (aged 19-72; M=46.2; SD=13.0; 75% female) with a physician-confirmed MS diagnosis who were receiving care in a university-affiliated MS center. Disease durations ranged from 1-37 years (M=10.7; SD=8.4). Participants completed the GAD-7 and GAD-2. Internal consistency was calculated for both measures. Researchers found:
- Internal consistency was excellent for the GAD-7 (Cronbach α=.91) and acceptable for the GAD-2 (α=.77), and the measures were highly correlated (r=.94).
- The GAD-2 had excellent overall accuracy for identifying clinically significant anxiety symptoms.
- A GAD-2 cut-off score of ≥3 provided an optimal balance of good sensitivity (0.87) and excellent specificity (0.92) for detecting clinically significant anxiety symptoms.
- Alternatively, a cut-off score of ≥2 provided excellent sensitivity (1.00) and fair specificity (0.76).
Hughes AJ, Dunn KM, Chaffee T, Bhattarai J, Beier M. Diagnostic and clinical utility of the GAD-2 for screening anxiety symptoms in individuals with multiple sclerosis. [Published online ahead of print June 30, 2018]. Arch Phys Med Rehab. doi:10.1016/j.apmr.2018.05.029.
This Week's Must Reads
Vegetable/Fruit Intake Benefits Cognitive Function, Neurology; ePub 2018 Nov 21; Yuan, Fondell, et al
Alzheimer Dementia and Age-Related Neuropathologies, Ann Neurol; ePub 2018 Nov 12; Boyle, Yu, et al
Kidney Function and Post-Stroke Mortality Examined, Stroke; ePub 2018 Nov 9; El Husseini, Fonarow, et al
Meditation May Help to Alleviate US Stroke Burden, J Stroke Cerebrovasc Dis; ePub 2018 Nov 24; Ambavane, et al
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
Must Reads in Multiple Sclerosis
Exposure to Animals Associated with Risk of MS, Mult Scler Relat Disord; ePub 2018 Nov 15; de Jong, et al
White Matter Tract Disruption, Fatigue Examined, Mult Scler Relat Disord; ePub 2018 Nov 9; Fuchs, et al
Coexistence of Multiple Sclerosis, Alzheimer Disease, Mult Scler Relat Disord; ePub 2018 Oct 27; Luczynski, et al
Body Mass Index Linked with Brain Volume Change, Neurology; ePub 2018 Nov 14; Mowry, Azevedo, et al
Detection of Whole Brain, Deep GM Atrophy in MS, PLoS One; ePub 2018 Nov 8; Chu, Kim, et al